| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.80 [0.59, 1.07] | | < 1 | | 56% | 4 studies (4/-) | 93.1 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.72 [0.59, 0.88] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.55 [0.45, 0.68] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.67 [0.50, 0.90] | | < 1 | | 53% | 4 studies (4/-) | 99.6 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 1.52 [0.75, 3.05] | | > 1 | | 77% | 4 studies (4/-) | 87.9 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.89 [0.41, 1.94] | | < 1 | | 37% | 4 studies (4/-) | 61.1 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 0.90 [0.49, 1.63] | | < 1 | | 79% | 4 studies (4/-) | 63.9 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 0.91 [0.56, 1.48] | | < 1 | | 0% | 4 studies (4/-) | 65.1 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.96 [0.51, 1.81] | | < 1 | | 72% | 3 studies (3/-) | 55.1 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 1.10 [0.64, 1.89] | | < 1 | | 0% | 1 study (1/-) | 35.9 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 1.36 [1.05, 1.78] | | < 1 | | 0% | 4 studies (4/-) | 1.1 % | low | not evaluable | high | non important | - |
| STRAE (any grade) | 0.61 [0.40, 0.93] | | < 1 | | 0% | 3 studies (3/-) | 98.9 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 0.48 [0.28, 0.84] | | < 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.62 [0.15, 2.50] | | < 1 | | 96% | 4 studies (4/-) | 74.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.75 [0.17, 3.37] | | < 1 | | 92% | 4 studies (4/-) | 64.6 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 0.93 [0.33, 2.65] | | < 1 | | 0% | 3 studies (3/-) | 55.2 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 0.60 [0.35, 1.03] | | < 1 | | 0% | 2 studies (2/-) | 96.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.28 [0.60, 2.75] | | < 1 | | 0% | 1 study (1/-) | 26.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Acute kidney injury TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.98 [0.18, 21.98] | | < 1 | | 0% | 2 studies (2/-) | 29.1 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.03 [0.00, 0.22] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.36 [0.05, 2.42] | | < 1 | | 34% | 3 studies (3/-) | 85.2 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 1.98 [0.18, 21.98] | | < 1 | | 0% | 2 studies (2/-) | 29.1 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.49 [0.04, 5.44] | | < 1 | | 0% | 2 studies (2/-) | 71.8 % | some concern | not evaluable | moderate | non important | - |
| Cough TRAE (grade 3-4) | 0.49 [0.01, 24.88] | | < 1 | | 0% | 1 study (1/-) | 63.6 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.28 [0.06, 1.43] | | < 1 | | 0% | 3 studies (3/-) | 93.6 % | some concern | not evaluable | moderate | non important | - |
| Dermatitis acneiform TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.71 [0.19, 2.65] | | < 1 | | 0% | 3 studies (3/-) | 69.2 % | some concern | not evaluable | moderate | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.50 [0.02, 15.30] | | < 1 | | 0% | 1 study (1/-) | 65.1 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 2.97 [0.15, 59.50] | | < 1 | | 0% | 1 study (1/-) | 24.1 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.83 [0.29, 2.39] | | < 1 | | 0% | 2 studies (2/-) | 63.6 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.08 [0.00, 1.41] | | < 1 | | 0% | 1 study (1/-) | 95.6 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 1.98 [0.18, 21.98] | | < 1 | | 0% | 2 studies (2/-) | 29.1 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.78 [0.08, 7.54] | | < 1 | | 0% | 3 studies (3/-) | 58.4 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.73 [0.24, 12.51] | | < 1 | | 0% | 3 studies (3/-) | 29.5 % | some concern | not evaluable | moderate | non important | - |
| Increased lipase level TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 1.02 [0.02, 52.03] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.16 [0.01, 3.32] | | < 1 | | 0% | 1 study (1/-) | 87.8 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.18 [0.03, 1.16] | | < 1 | | 0% | 3 studies (3/-) | 96.4 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.04 [0.01, 0.20] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Pneumonia TRAE (grade 3-4) | 1.02 [0.06, 16.62] | | < 1 | | 0% | 1 study (1/-) | 49.5 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.93 [0.36, 2.44] | | < 1 | | 2% | 3 studies (3/-) | 55.6 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 0.69 [0.04, 10.98] | | < 1 | | 0% | 2 studies (2/-) | 60.4 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 1.66 [0.35, 7.91] | | < 1 | | 0% | 3 studies (3/-) | 26.4 % | some concern | not evaluable | moderate | non important | - |
| Stomatitis TRAE (grade 3-4) | 2.05 [0.07, 62.21] | | < 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.03 [0.00, 0.42] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.07 [0.00, 1.18] | | < 1 | | 0% | 1 study (1/-) | 96.6 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Alopecia AE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.36 [0.07, 1.90] | | < 1 | | 87% | 2 studies (2/-) | 88.4 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia AE (grade 3-4) | 0.58 [0.04, 9.58] | | < 1 | | 0% | 2 studies (2/-) | 64.5 % | low | not evaluable | high | non important | - |
| Asthenia AE (grade 3-4) | 1.01 [0.45, 2.23] | | < 1 | | 0% | 2 studies (2/-) | 49.5 % | some concern | not evaluable | moderate | non important | - |
| Back pain AE (grade 3-4) | 0.42 [0.08, 2.08] | | < 1 | | 0% | 3 studies (3/-) | 85.6 % | some concern | not evaluable | moderate | non important | - |
| Constipation AE (grade 3-4) | 0.90 [0.14, 5.96] | | < 1 | | 0% | 3 studies (3/-) | 54.4 % | some concern | not evaluable | moderate | non important | - |
| Cough AE (grade 3-4) | 1.10 [0.19, 6.41] | | < 1 | | 0% | 3 studies (3/-) | 45.8 % | low | not evaluable | high | non important | - |
| Decreased appetite AE (grade 3-4) | 0.81 [0.16, 4.11] | | < 1 | | 38% | 2 studies (2/-) | 60.2 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea AE (grade 3-4) | 0.49 [0.16, 1.45] | | < 1 | | 0% | 3 studies (3/-) | 90.2 % | some concern | not evaluable | moderate | non important | - |
| Dry skin AE (grade 3-4) | 0.70 [0.01, 37.74] | | < 1 | | 0% | 1 study (1/-) | 56.9 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 0.98 [0.47, 2.05] | | < 1 | | 0% | 3 studies (3/-) | 52.0 % | some concern | not evaluable | moderate | non important | - |
| Fatigue AE (grade 3-4) | 0.58 [0.09, 3.82] | | < 1 | | 61% | 2 studies (2/-) | 71.3 % | some concern | not evaluable | moderate | non important | - |
| Headache AE (grade 3-4) | 0.24 [0.02, 2.71] | | < 1 | | 0% | 1 study (1/-) | 87.3 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 0.99 [0.03, 29.48] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.25 [0.05, 1.37] | | < 1 | | 0% | 3 studies (3/-) | 94.4 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia AE (grade 3-4) | 0.35 [0.01, 13.04] | | < 1 | | 79% | 2 studies (2/-) | 71.3 % | some concern | not evaluable | moderate | non important | - |
| Pneumonia AE (grade 3-4) | 1.22 [0.57, 2.65] | | < 1 | | 0% | 2 studies (2/-) | 30.4 % | low | not evaluable | high | non important | - |
| Pneumonitis AE (grade 3-4) | 1.32 [0.51, 3.43] | | < 1 | | 0% | 1 study (1/-) | 28.2 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.69 [0.07, 6.72] | | < 1 | | 0% | 3 studies (3/-) | 62.5 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia AE (grade 3-4) | 2.66 [0.28, 25.19] | | < 1 | | 0% | 2 studies (2/-) | 19.8 % | some concern | not evaluable | moderate | non important | - |
| Rash AE (grade 3-4) | 1.70 [0.31, 9.33] | | < 1 | | 0% | 3 studies (3/-) | 27.3 % | some concern | not evaluable | moderate | non important | - |
| Stomatitis AE (grade 3-4) | 0.70 [0.01, 37.74] | | < 1 | | 0% | 1 study (1/-) | 56.9 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.05 [0.01, 0.38] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.54 [0.16, 1.86] | | < 1 | | 0% | 1 study (1/-) | 83.5 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 2.88 [0.30, 27.79] | | < 1 | | 0% | 1 study (1/-) | 18.2 % | NA | not evaluable | | non important | - |
